Patheon Appoints New President of Pharmaceutical Development Services

January 12, 2016
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-02-03-2016, Volume 12, Issue 2

Patheon announced the appointment of Gilles Cottier as president of the company’s pharmaceutical development services.

Patheon announced the appointment of Gilles Cottier as president of the company’s pharmaceutical development services (PDS) division, effective immediately.

According to a Jan. 12, 2016 press announcement from the company, Cottier will serve as a member of Patheon’s executive committee and will report to chief executive officer James Mullen. Cottier will assume responsibilities of the PDS segment from Michael Lehmann, who previously led both Global PDS and Global Sales and Marketing for the company. Lehmann will now focus specifically on Sales and Marketing

Cottier joins Patheon after spending 25-years at Sigma-Aldrich Corporation, where he was executive vice-president and president of the Sigma-Aldrich Fine Chemicals (SAFC) commercial unit. Sigma-Aldrich was purchased in November 2015 by Merck KGaA, Darmstadt, Germany in a $17-billion acquisition. The acquisition combined Merck’s existing life science business EMD Millipore with Sigma-Aldrich, now MilliporeSigma

Patheon said Cottier is part of a larger realignment effort by the company to create three distinct business segments-drug product services, drug substance services, and PDS.  

Source: Patheon/Business Wire

 

 

Related Content:

Industry News | PharmTech News